Skip to main content
SpringerLink
Log in

Hereditary Breast Cancer

  • Chapter
  • First Online:
Hereditary Breast and Ovarian Cancer

  • 532 Accesses

Abstracts

In hereditary breast cancer, the different strategies from sporadic cancer might be required due to its vulnerable feature. We reviewed the published data of breast cancers with germline BRCA1/BRCA2, TP53, PTEN, CDH1, PALB2, CHEK2, ATM, and STK11 focusing on the treatment. The standard of locoregional treatment including surgery and radiation therapy (RT) should be considered in hereditary breast cancer except for TP53-related breast cancer as in sporadic breast cancer. Mastectomy is recommended without RT for germline TP53 mutation carriers. Because there is a lack of reliable data about treatment of hereditary breast cancer, the discussion about the risk of both recurrence and new breast cancer is encouraged. Chemotherapy including platinum is recommended for metastatic breast cancer with BRCA1/BRCA2 mutation. However, there is no data supporting the use of platinum in (neo)adjuvant settings for early breast cancer with BRCA1/BRCA2 mutation. More researches about treatment for hereditary breast cancer are considered indispensable.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Institute. NC. Genetics of breast and gynecologic cancers (PDQ®) - health professional version. 2019. https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq.

  2. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.

    Google Scholar 

  3. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643–6.

    Article  CAS  PubMed  Google Scholar 

  4. Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011;17:1082–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Rummel S, Varner E, Shriver CD, Ellsworth RE. Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer. Breast Cancer Res Treat. 2013;137:119–25.

    Article  PubMed  Google Scholar 

  6. Friebel TM, Andrulis IL, Balmaña J, et al. BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. Hum Mutat. 2019;40:1781–96.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–502.

    Article  CAS  PubMed  Google Scholar 

  8. Nakamura S, Takahashi M, Tozaki M, et al. Prevalence and differentiation of hereditary breast and ovarian cancers in Japan. Breast Cancer. 2015;22:462–8.

    Article  PubMed  Google Scholar 

  9. van den Broek AJ, Schmidt MK, van 't Veer LJ, et al. Prognostic impact of breast-conserving therapy versus mastectomy of BRCA1/2 mutation carriers compared with noncarriers in a consecutive series of young breast cancer patients. Ann Surg. 2019;270:364–72.

    Article  PubMed  Google Scholar 

  10. Nilsson MP, Hartman L, Kristoffersson U, et al. High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer. Breast Cancer Res Treat. 2014;147:571–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Pierce LJ, Phillips KA, Griffith KA, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat. 2010;121:389–98.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Yao K, Liederbach E, Tang R, et al. Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature. Ann Surg Oncol. 2015;22:370–6.

    Article  PubMed  Google Scholar 

  13. Manning AT, Wood C, Eaton A, et al. Nipple-sparing mastectomy in patients with BRCA1/2 mutations and variants of uncertain significance. Br J Surg. 2015;102:1354–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2015;136:668–77.

    CAS  PubMed  Google Scholar 

  15. Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014;348:g226.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. Soenderstrup IMH, Laenkholm AV, Jensen MB, et al. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG. Acta Oncol. 2018;57:95–101.

    Article  CAS  PubMed  Google Scholar 

  17. Evans DG, Ingham SL, Baildam A, et al. Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat. 2013;140:135–42.

    Article  CAS  PubMed  Google Scholar 

  18. Valachis A, Nearchou AD, Lind P. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014;144:443–55.

    Article  CAS  PubMed  Google Scholar 

  19. Drooger J, Akdeniz D, Pignol JP, et al. Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age. Breast Cancer Res Treat. 2015;154:171–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Pierce LJ, Strawderman M, Narod SA, et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol. 2000;18:3360–9.

    Article  CAS  PubMed  Google Scholar 

  21. Park H, Choi DH, Noh JM, et al. Acute skin toxicity in Korean breast cancer patients carrying BRCA mutations. Int J Radiat Biol. 2014;90:90–4.

    Article  CAS  PubMed  Google Scholar 

  22. Shanley S, McReynolds K, Ardern-Jones A, et al. Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clin Cancer Res. 2006;12:7025–32.

    Article  CAS  PubMed  Google Scholar 

  23. Hahnen E, Lederer B, Hauke J, et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncol. 2017;3:1378–85.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Loibl S, O'Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19:497–509.

    Article  CAS  PubMed  Google Scholar 

  25. Caramelo O, Silva C, Caramelo F, et al. The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis. Hered Cancer Clin Pract. 2019;17:11.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat Med. 2018;24:628–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Zhang J, Lin Y, Sun XJ, et al. Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Ann Oncol. 2018;29:1741–7.

    Article  CAS  PubMed  Google Scholar 

  28. Templeton AJ, Gonzalez LD, Vera-Badillo FE, et al. Interaction between hormonal receptor status, age and survival in patients with BRCA1/2 germline mutations: a systematic review and meta-regression. PLoS One. 2016;11:e0154789.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Goodwin PJ, Phillips KA, West DW, et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an international prospective breast cancer family registry population-based cohort study. J Clin Oncol. 2012;30:19–26.

    Article  PubMed  Google Scholar 

  30. Copson ER, Maishman TC, Tapper WJ, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018;19:169–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Fortuno C, James PA, Spurdle AB. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome. Hum Mutat. 2018;39:1764–73.

    Article  CAS  PubMed  Google Scholar 

  32. Heymann S, Delaloge S, Rahal A, et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol. 2010;5:104.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Henry E, Villalobos V, Million L, et al. Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome. J Natl Compr Cancer Netw. 2012;10:939–42.

    Article  Google Scholar 

  34. Ferrarini A, Auteri-Kaczmarek A, Pica A, et al. Early occurrence of lung adenocarcinoma and breast cancer after radiotherapy of a chest wall sarcoma in a patient with a de novo germline mutation in TP53. Familial Cancer. 2011;10:187–92.

    Article  PubMed  Google Scholar 

  35. Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer. 2001;96:238–42.

    Article  CAS  PubMed  Google Scholar 

  36. Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet. 2013;50:255–63.

    Article  CAS  PubMed  Google Scholar 

  37. Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18:400–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Genetic/familial high-risk assessment: breast and ovarian. http://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.

  39. Dossus L, Benusiglio PR. Lobular breast cancer: incidence and genetic and non-genetic risk factors. Breast Cancer Res. 2015;17:37.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. van der Post RS, Vogelaar IP, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015;52:361–74.

    Article  PubMed  CAS  Google Scholar 

  41. Corso G, Intra M, Trentin C, et al. CDH1 germline mutations and hereditary lobular breast cancer. Familial Cancer. 2016;15:215–9.

    Article  CAS  PubMed  Google Scholar 

  42. Tischkowitz M, Xia B. PALB2/FANCN: recombining cancer and Fanconi anemia. Cancer Res. 2010;70:7353–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Antoniou AC, Foulkes WD, Tischkowitz M. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371:1651–2.

    Article  PubMed  CAS  Google Scholar 

  44. Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371:497–506.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. Cybulski C, Kluźniak W, Huzarski T, et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. Lancet Oncol. 2015;16:638–44.

    Article  CAS  PubMed  Google Scholar 

  46. Easton DF, Pharoah PD, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015;372:2243–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Lee A, Mavaddat N, Wilcox AN, et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med. 2019;21:1708–18.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Kriege M, Hollestelle A, Jager A, et al. Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy. Br J Cancer. 2014;111:1004–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Weischer M, Nordestgaard BG, Pharoah P, et al. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol. 2012;30:4308–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Fletcher O, Johnson N, Dos Santos SI, et al. Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls. Cancer Epidemiol Biomark Prev. 2009;18:230–4.

    Article  CAS  Google Scholar 

  51. Schmidt MK, Tollenaar RA, de Kemp SR, et al. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol. 2007;25:64–9.

    Article  CAS  PubMed  Google Scholar 

  52. Meyer A, John E, Dörk T, et al. Breast cancer in female carriers of ATM gene alterations: outcome of adjuvant radiotherapy. Radiother Oncol. 2004;72:319–23.

    Article  CAS  PubMed  Google Scholar 

  53. Bremer M, Klöpper K, Yamini P, et al. Clinical radiosensitivity in breast cancer patients carrying pathogenic ATM gene mutations: no observation of increased radiation-induced acute or late effects. Radiother Oncol. 2003;69:155–60.

    Article  CAS  PubMed  Google Scholar 

  54. Iannuzzi CM, Atencio DP, Green S, et al. ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J Radiat Oncol Biol Phys. 2002;52:606–13.

    Article  CAS  PubMed  Google Scholar 

  55. Andreassen CN, Overgaard J, Alsner J, et al. ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys. 2006;64:776–83.

    Article  PubMed  Google Scholar 

  56. Bernstein JL, Concannon P. ATM, radiation, and the risk of second primary breast cancer. Int J Radiat Biol. 2017;93:1121–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Broeks A, Braaf LM, Huseinovic A, et al. Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. Breast Cancer Res. 2007;9:R26.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  58. Su Y, Swift M. Outcomes of adjuvant radiation therapy for breast cancer in women with ataxia-telangiectasia mutations. JAMA. 2001;286:2233–4.

    Article  CAS  PubMed  Google Scholar 

  59. Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12:3209–15.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan

    Minoru Miyashita & Takanori Ishida

Authors
  1. Minoru Miyashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takanori Ishida
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Minoru Miyashita .

Editor information

Editors and Affiliations

  1. Department of Breast Surgical Oncology, Showa University, School of Medicine, Tokyo, Japan

    Seigo Nakamura

  2. Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan

    Daisuke Aoki

  3. Department of Molecular Genetics, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan

    Yoshio Miki

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Miyashita, M., Ishida, T. (2021). Hereditary Breast Cancer. In: Nakamura, S., Aoki, D., Miki, Y. (eds) Hereditary Breast and Ovarian Cancer . Springer, Singapore. https://doi.org/10.1007/978-981-16-4521-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-981-16-4521-1_6

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-16-4520-4

  • Online ISBN: 978-981-16-4521-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation